New research from Oregon Health & Science University reveals negative health consequences for people who are overweight and ignore their body’s signals to sleep at night, with specific differences between men and women.

The study published this week in The Journal of Clinical Endocrinology & Metabolism.

“This study builds support for the importance of good sleep habits,” said lead author Brooke Shafer, Ph.D., a postdoctoral researcher in the Sleep, Chronobiology and Health Laboratory in the OHSU School of Nursing. “Sleep practices, like going to bed when you’re tired or setting aside your screen at night, can help to promote good overall health.”

The study recruited 30 people, split evenly between men and women. All had a body mass index above 25, which put them into an overweight or obese category.

[…]

Generally healthy participants contributed a saliva sample every 30 minutes until late in the night at a sleep lab on OHSU’s Marquam Hill campus to determine the time at which their body started naturally producing the hormone melatonin. Melatonin is generally understood to begin the process of falling asleep, and its onset varies with an individual’s internal biological clock.

Participants then went home and logged their sleep habits over the following seven days.

Researchers assessed the time difference between melatonin onset and average sleep timing for each participant, categorizing them into two groups: those who had a narrow window, with a short time duration between melatonin onset and sleep, and those with a wide window, with a longer duration between melatonin onset and sleep. A narrow window suggests someone who is staying awake too late for their internal body clock and is generally associated with poorer health outcomes.

The new study confirmed a variety of potentially harmful health measures in the group that went to sleep closer to melatonin onset.

It also found key differences between men and women. Men in this group had higher levels of belly fat and fatty triglycerides in the blood, and higher overall metabolic syndrome risk scores than the men who slept better. Women in this group had higher overall body fat percentage, glucose and resting heart rates.

[…]

Source: Good sleep habits important for overweight adults | ScienceDaily

Doctors have begun trialling the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

[…]

The jab uses messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime the body to fight cancer cells expressing these markers.

The aim is to strengthen a person’s immune response to cancer while leaving healthy cells untouched, unlike chemotherapy.

[…]

six consecutive injections five minutes apart over 30 minutes at the National Institute for Health Research UCLH Clinical Research Facility on Tuesday.

Each jab contained different RNA strands. He will get the vaccine every week for six consecutive weeks, and then every three weeks for 54 weeks.

Lee said: “We hope adding this additional treatment will stop the cancer coming back because a lot of time for lung cancer patients, even after surgery and radiation, it does come back.”

[…]

Source: World-first lung cancer vaccine trials launched across seven countries | Lung cancer | The Guardian